

Lialda® (mesalamine) – Expanded indication

- On June 26, 2020, the <u>FDA approved</u> Takeda's <u>Lialda (mesalamine)</u>, for the treatment of mildly to moderately active ulcerative colitis in pediatric patients weighing at least 24 kg.
- Lialda is also approved for the induction and maintenance of remission in adult patients with mildly to moderately active ulcerative colitis.
- Lialda is also available generically.
- The approval of Lialda for the expanded indication was based on a randomized, double-blind study in pediatric patients with mildly to moderately active ulcerative colitis. The study consisted of two treatment phases, an initial 8-week phase and a 26-week phase. The overall population consisted of 105 patients, of whom 27 patients participated in both the 8-week and 26-week phases. Patients received a low or a high weight-based dosage of Lialda. The primary endpoint was defined by the partial Ulcerative Colitis Disease Activity Index (UC-DAI) less than or equal to 1 (with rectal bleeding equal to 0, stool frequency less than or equal to 1, and Physician's Global Assessment equal to 0).
 - In the 8-week phase, of the 26 patients in the recommended Lialda dosage arm, 65% achieved the primary endpoint.
 - In the 26-week phase, of the 42 patients in the recommended Lialda dosage arm, 55% achieved the primary endpoint. The arm with a higher than recommended Lialda dosage was not more effective and is not recommended.
- The most common adverse reactions (≥ 5%) with Lialda use in pediatric patients were abdominal pain, upper respiratory tract infection, vomiting, anemia, headache, and viral infection.
- The recommended oral dosage of Lialda in pediatric patients weighing at least 24 kg who can swallow tablets whole is shown in the table below.
 - Refer to the Lialda drug label for dosing in adult patients.

Weight of pediatric patient	Once daily Lialda dosage	
	Week 0 to week 8	After week 8
24 kg to 35 kg	2.4 g (two 1.2-g tablets)	1.2 g (one 1.2-g tablet)
Greater than 35 kg to 50 kg	3.6 g (three 1.2-g tablets)	2.4 g (two 1.2-g tablets)
Greater than 50 kg	4.8 g (four 1.2-g tablets)	2.4 g (two 1.2-g tablets)



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.